OSI-906 is a potent, selective orally active inhibitor of the insulin-like growth factor-1 receptor (IGF-1R).OSI-906 demonstrated robust anti-tumor activity in an IGF-1R dependent xenograft model when administered orally once a day at doses of 25 and 75 mg/kg. OSI-906 not only slowed the growth of IGF-1R-dependent tumors, but also reduced proliferation and/or survival of a broad panel of tumor cell lines. Specifically, among a panel of 28 human tumor cell lines, OSI-906 potently (EC50 < 400 nM) reduced growth of 15 cell lines representative of colorectal, NSCLC, pancreatic, breast and pediatric cancers.
Biotool LLC
聯(lián)系商家時請?zhí)峒癱hemicalbook,有助于交易順利完成!